Trials / Completed
CompletedNCT01378416
Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
A Phase I Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the pharmacokinetics (PK) of decitabine administered to patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decitabine (Dacogen) | Intravenous injection; total dose-per-cycle was 135 mg/m\^2 of decitabine. |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2006-01-01
- Completion
- 2007-06-01
- First posted
- 2011-06-22
- Last updated
- 2011-07-12
- Results posted
- 2011-06-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01378416. Inclusion in this directory is not an endorsement.